Chinese biotech company Elpiscience Biopharmaceuticals Co. has completed a US$35 million series A+ round of financing led by Hillhouse Capital, with participation from CDH Investments and Lilly Asia Ventures (LAV).
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?